


SEE THE DIFFERENCE, MAKE A DIFFERENCE.

EFFECTIVE ENHANCEMENT AT HALF THE GD DOSE.*1-3



VUEWAY® has the **highest relaxivity** of all GBCAs today combined with **high stability**.^{†4}

High relaxivity is synonymous with **high potency**, which means **high efficacy**.

A high-potency GBCA can **achieve the same desired contrast effect at a reduced gadolinium dose**.⁵⁻⁸

▶ The degree of contrast enhancement and diagnostic efficacy produced by GBCAs on MR images depends on relaxivity and injected dose (time-dependent, local concentration in tissue).⁵⁻⁷

Before use, please refer to your locally approved SmPC.

The individual who appears is for illustrative purposes.
The person depicted is a model and not a real healthcare professional.

VISIT [Bracco.com](https://www.bracco.com) FOR MORE INFORMATION

GL-VW-2300013




SEE THE DIFFERENCE, MAKE A DIFFERENCE.


VUEWAY® - ENHANCED MRI OF THE CNS AND BODY AT 0.05 MMOL/KG VS. GADOBUTROL AT 0.1 MMOL/KG*†

Vueway
(gadopiclenol) injection


BRACCO
LIFE FROM INSIDE




Gadopiclenol 0.05 mmol/kg (Post-T1 SE)



Gadobutrol 0.1 mmol/kg (Post-T1 SE)



Gadopiclenol 0.05 mmol/kg



Gadobutrol 0.1 mmol/kg

▶ Thanks to high potency, lesion detection and characterization can be achieved at a reduced Gd dose across a broad spectrum of field strengths and examinations.¹⁻³

Above, MRI of the CNS:

Clinical case of an 80-year-old patient with cerebellar metastasis[§]

Right, MRI of the Body:

Clinical case of a 68-year-old female patient with liver metastasis from rectal cancer (enhancing lesion in left liver lobe, arterial phase)[#]

*Half the gadolinium dose compared to other macrocyclic GBCAs at a Gd dose of 0.1 mmol/kg in approved indications.

†Together with Elucirem™ (gadopiclenol).

‡All images shown are representative images from referenced studies. Individual results may vary.

§From Phase III PICTURE Clinical Trial of MRI in the CNS: Study GDX-44-010. Data on file.

#From Phase III PROMISE Clinical Trial of MRI in the Body: Study GDX-44-011. Data on file.

CNS: central nervous system; GBCA: gadolinium-based contrast agent; MRI: magnetic resonance imaging; SE: spin echo; T: tesla.

1. VUEWAY® SmPC 2023.
2. Loevner L, et al. Invest Radiol. 2023 May;1:58(5):307-313.
3. Kuhl C, et al. Radiology. 2023 Jul;308(1).
4. Robic C, et al. Invest Radiol. 2019;54: 475-484.
5. Tweedle MF, et al. Supplement to Applied Radiology, May 2014.
6. Jacques V, et al. Invest Radiol. 2010 Oct;45(10):613-624.
7. Lancelot E, et al. Invest Radiol. 2020 Sep;55(9):578-588.
8. Vaneckova M, et al. Am J Neuroradiol. 2015;36:1589-1590.